GlassScriptPhysician profile
Andrew S Frazier
NPI 1902269566
$32,040.45
in general payments reported to CMS, 2019-2025
21 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $22K · 2021: $6,133 · 2022: $2,453 · 2023: $1,076 · 2024: $576 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,737 · Travel and Lodging: $36.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,737.05 |
| Travel and Lodging | $36.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $12,505.90 | 2020 | |
| Abbott Laboratories | $9,553.12 | 2020-2023 | Proclaim, Eterna |
| Boston Scientific Corporation | $6,131.07 | 2021-2025 | Intracept |
| Nevro Corp. | $1,481.37 | 2020-2024 | Senza |
| Medtronic, INC. | $623.53 | 2021-2024 | Intellis Adaptivestim, Synchromedii |
| Nalu Medical, INC. | $528.10 | 2020-2023 | Nalu Neurostimulation System |
| Painteq LLC | $227.50 | 2022 | |
| Relievant Medsystems, INC. | $184.02 | 2023 | Intracept |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $129.02 | 2022-2023 | Relistor |
| Globus Medical, INC. | $101.60 | 2025 | Senza |
| Spr Therapeutics, INC | $92.23 | 2022-2024 | Sprint Pns System |
| Averitas Pharma INC. | $82.91 | 2024 | Qutenza |
| Scilex Pharmaceuticals INC. | $77.82 | 2022-2023 | Ztlido |
| Vertos Medical, INC. | $76.97 | 2022-2024 | Mild Device Kit |
| Foundation Fusion Solutions, LLC | $72.55 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $68.20 | 2022-2023 | |
| Pacira Pharmaceuticals Incorporated | $29.75 | 2023 | Iovera, Zilretta |
| Horizon Therapeutics Plc | $24.70 | 2022 | |
| Collegium Pharmaceutical, INC. | $22.72 | 2023 | Belbuca |
| Tersera Therapeutics LLC | $15.24 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Frazier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.